FDA
-
-
-
-
-
-
-
Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
-
-
-
-
-
-
-
Niagen Bioscience doubles share buyback program to $20 million
-
-
-
-
-
-
-
Niagen Bioscience sells ChromaDex Reference Standards to LGC for cash
-
-
-
-
-
-
-
Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*
-
-
-
-
-
-
-
Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
-
-
-
-
-
-
-
Niagen Bioscience to Present at Canaccord Genuity’s 45th Annual Growth Conference
-
-
-
-
-
-
-
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder
-
323,592 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

